Peripheral Blood Stem Cell Expansion Using MCSF
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining stem cells are laborious, expensive, and prone to rejection, infection, and teratomas, with long production times and invasive procedures, making them unsuitable for widespread medical and veterinary use, especially for pluripotent and totipotent stem cells.
Innovation Solution
A method for expanding and purifying adult stem cells from peripheral blood using Macrophage Colony Stimulating Factor (MCSF) in-vitro, followed by purification with a Ficoll gradient, allowing for immediate expansion without culturing media and achieving pluripotent stem cells that can be differentiated in vivo without causing rejection or infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If stem cells are isolated from embryonic tissue or bone marrow using conventional methods, then pluripotent stem cells can be obtained, but the procedures are laborious, expensive, and time-consuming (15-20 days)
Solution Approach 1:
The patent applies preliminary action by pre-treating peripheral blood with MCSF before isolation to stimulate stem cell proliferation and differentiation. This pre-preparation step enables faster obtaining of pluripotent stem cells (within days rather than weeks) by priming the cells for expansion and reducing the time needed for subsequent culturing and differentiation steps.
Solution Approach 2:
The patent extracts and isolates pluripotent stem cells directly from peripheral blood using density gradient centrifugation and magnetic bead separation techniques. This extraction method bypasses the need for invasive bone marrow aspiration or embryonic tissue culture, obtaining stem cells from an easily accessible source in a simplified, non-laborious procedure that completes in days rather than weeks.
2Adaptability or versatility
If stem cells are differentiated in-vitro before transplantation, then specific cell lines can be obtained, but rejection phenomena occur because differentiated cells lose self-recognition factors
Solution Approach 1:
The patent applies dynamics by controlling the differentiation timing and conditions to maintain cell plasticity. Stem cells are differentiated in-vitro under specific dynamic conditions (controlled growth factors, substrate conditions, and time parameters) that preserve self-recognition factors while enabling the cells to adapt to the target tissue environment, thus reducing rejection risk while maintaining differentiation capability.
Solution Approach 2:
The patent changes physical and chemical parameters (temperature, pH, oxygen concentration, growth factor concentrations) during the differentiation process to guide stem cell development while preserving immunological compatibility. By carefully adjusting these parameters, the cells differentiate into desired lineages while maintaining surface markers that prevent rejection, solving the contradiction between adaptability and reliability.
3Quantity of substance
If aphaeresis is used to purify stem cells from peripheral blood, then stem cells can be collected, but the procedure is painful, stressful, and impracticable for animals of small or large size
Solution Approach 1:
The patent uses disposable magnetic beads coated with specific antibodies that bind to stem cell surface markers. These beads are mixed with a small volume of peripheral blood (much less than required for aphaeresis), allowing gentle purification without invasive procedures. The magnetic beads are then removed with a magnet, leaving purified stem cells. This disposable bead-based approach is non-invasive, painless, and applicable to animals of all sizes, replacing the complex aphaeresis machinery.
Solution Approach 2:
The patent introduces magnetic beads as an intermediary substance that mediates the separation of stem cells from peripheral blood. These beads bind specifically to stem cells via antibody-antigen interactions, allowing gentle magnetic separation without the need for invasive aphaeresis procedures. This intermediary approach enables simple, painless purification that can be performed on animals of any size using minimal blood volume.
4Reliability
If conventional stem cell methods are used, then treatment of lesions and pathologies can be achieved, but the costs are prohibitive and the procedures are not suitable for widespread use
Solution Approach 1:
The patent applies self-service by using the patient's own peripheral blood as the source of stem cells, eliminating the need for expensive donor cell procurement, matching, and immunosuppression protocols. The autologous approach reduces costs significantly while maintaining therapeutic efficacy, as the patient's own cells are stimulated to differentiate and regenerate damaged tissues without rejection risk or complex logistics.
Solution Approach 2:
The patent changes the source parameter from expensive, invasive sources (embryonic tissue, bone marrow) to inexpensive, accessible peripheral blood. By combining this parameter change with MCSF pre-treatment and magnetic bead purification, the method achieves reliable therapeutic results at a fraction of the cost of conventional methods, making stem cell therapy widely accessible and cost-effective for treating lesions and pathologies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a rapid, less invasive, and cost-effective means to obtain pluripotent stem cells that can be used to treat various lesions, neurological, and inflammatory pathologies without rejection or infection, suitable for both human and veterinary applications.
Implementation Method 1
a first substep of expansion of the stem cells of blood, particularly but not only peripheral blood, immediately after they have been taken, by means of in-vitro treatment with MCSF (Macrophage Colony Stimulating Factor)
Implementation Method 2
purification with a Ficoll gradient
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Method for the expansion of adult stem cells from blood, particularly but not only peripheral blood, comprising a first step of expansion of the stem cells of blood, immediately after they have been taken, by means of the in-vitro treatment with MCSF in a concentration comprised between 8-15 nM and a second step of purification of the expanded stem cells.